The information presented on this webpage does not constitute an offer to acquire, subscribe for or otherwise trade in shares or other securities of Modus Therapeutics. Any invitation to the relevant persons to subscribe for shares in Modus will be made solely through the Swedish langugage prospectus published by Modus. No action has been, or will be, taken by Modus to permit a public offering in any jurisdiction other than Sweden.
The offer and the information on this webpage may not be announced, published or distributed, directly or indirectly, in or into Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, the United Kingdom, South Africa, the United States or any other jurisdiction where such action, in whole or in part, would be subject to legal restrictions or would require additional prospectuses, registration or measures other than those required under Swedish law. The information on this webpage may also not be forwarded or reproduced in a manner that conflicts with such restrictions or would entail such requirements. Any violation of these instructions may constitute a breach of applicable securities laws.
Neither the unit rights, paid and subscribed units (BTU), new shares nor warrants issued in the offer have been, or will be, registered under the United States Securities Act of 1933, as amended, and may not be offered, subscribed, exercised, pledged, sold, resold, delivered or transferred, directly or indirectly, in or into the United States except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. The offer is likewise not directed to persons resident in Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, the United Kingdom, South Africa or any other jurisdiction where participation would require additional prospectuses, registration or measures other than those required under Swedish law.
